Error in Figure
In the original publication [1], there was a mistake in the right side of Figure 1A. The image of a crystal violet plate of MDA-MB-231 cells was inadvertently duplicated from a previous manuscript (reference [27] in original publication [1]). The corrected Figure 1A and its quantification have been updated in the figure below. A new set of experiments was performed to replace the duplicated crystal violet plate and generate a new quantification graph. The authors apologize for any inconvenience caused and state that the scientific conclusions remained unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 1.
Oncolytic adenovirus expressing mCherry (OAdmCherry) and temozolomide (TMZ) have a cell-killing effect on human triple-negative breast cancer (TNBC) cells: (A) HCC1937 and MDA-MB-231 cells were infected with OAdmCherry or adenovirus expressing green fluorescent protein (AdGFP) at different multiplicity of infection concentrations for 72 h. Crystal violet staining was used to evaluate cytopathic effect (CPE). A representative staining of three independent experiments is shown. (B) Relative cell survival was calculated by measuring the absorbance of solubilized dye at 590 nm. (C) HCC1937 and MDA-MB-231 cells were treated with TMZ at different concentrations for 72 h. Cell survival was calculated by MTT assay. Results represent the mean of three repeated measurements ± standard deviation (SD; error bars) (* p < 0.05).
Reference
- Garza-Morales, R.; Gonza-lez-Ramos, R.; Chiba, A.; de Oca-Luna, R.M.; McNally, L.R.; McMasters, K.M.; Gomez-Gutierrez, J.G. Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. Cancers 2018, 10, 144. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).